Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

BACKGROUND: Therapeutic cancer vaccines have shown activity in metastatic castration-resistant prostate cancer (mCRPC), and methods are being assessed to enhance their efficacy. Ipilimumab is an antagonistic monoclonal antibody that binds cytotoxic T-lymphocyte-associated protein 4, an immunomodulat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Lancet Oncol
Prif Awduron: Madan, Ravi A, Mohebtash, Mahsa, Arlen, Philip M, Vergati, Matteo, Rauckhorst, Myrna, Steinberg, Seth M, YTsang, Kwong, Poole, Diane J, Parnes, Howard L, Wright, John J, Dahut, William L, Schlom, Jeffrey, Gulley, James L
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2012
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6359905/
https://ncbi.nlm.nih.gov/pubmed/22326924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(12)70006-2
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg